Short-course imatinib (IM) added to chemotherapy improves early but not long-term outcome in adult Ph/BCR-ABL+ acute lymphoblastic leukemia (ALL) : 5-year follow-up results of study NILG-09

Bassan, R.; Intermesoli, T.; Oldani, E.; Rossi, G.; Borlenghi, E.; Pogliani, E.M.; Terruzzi, E.; Fabris, P.; Di Bona, E.; Gianfaldoni, G.; Romani, C.; Cortelezzi, A.; Mattei, D.; Spinelli, O.; Rambaldi, A.

Short-course imatinib (IM) added to chemotherapy improves early but not long-term outcome in adult Ph/BCR-ABL+ acute lymphoblastic leukemia (ALL) : 5-year follow-up results of study NILG-09 / R. Bassan, T. Intermesoli, E. Oldani, G. Rossi, E. Borlenghi, E.M. Pogliani, E. Terruzzi, P. Fabris, E. Di Bona, G. Gianfaldoni, C. Romani, A. Cortelezzi, D. Mattei, O. Spinelli, A. Rambaldi. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 93:Suppl. 1(2008), pp. 366-367. ((Intervento presentato al 13. convegno Congress of the European hematology association tenutosi a Copenhagen nel 2008.